|
|
|
18.06.25 - 22:12
|
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--$GERN--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 372,000 shares of common stock, to 16 newly hired employees as an inducement material to their acceptance of employment with Geron.
The stock options and RSUs were granted on June 17, 2025. The stock options have an exercise price of $1.45 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of each employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continu...
|
|
|
19.05.25 - 22:18
|
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 137,000 shares of common stock, to six newly hired employees as an inducement material to their acceptance of employment with Geron.
The stock options and RSUs were granted on May 16, 2025. The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of each employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employm...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.25 - 16:18
|
Geron Corp. Posts Narrower Loss In Q1 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Geron Corp. (GERN) posted a first quarter net loss of $19.8 million, or $0.03 per share, compared to a loss of $55.4 million, or $0.09 per share, prior year. Total net reven......
|
|
|
|
|
07.05.25 - 13:06
|
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
|
|
|
Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat
Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026
Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026
Company to host conference call and webcast today, May 7 at 8:00 a.m. ET
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2025 and recent business highlights.
"We are confident in the long-term potential of RYTELO as an important therapeutic for eligible patients with lower-risk-MDS and are sharply focused on maximizing the U.S. commercial opportunity,” said Dawn ...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
